曲克芦丁脑蛋白辅助治疗急性脑梗死的临床分析

Clinical Analysis of Erbium Rutin Brain Protein in the Treatment of Acute Cerebral Infarction

目的探讨曲克芦丁脑蛋白辅助治疗急性脑梗死的临床疗效。方法方便选取该院2015年7月—2017年10月期间收治的60例急性脑梗死患者作为研究对象,根据不同治疗方式平分为研究组、对照组,各30例。对照组给予0.5 g血栓通粉针+250 mL生理盐水静脉滴注,另给予100 mg拜阿司匹林口服。研究组在常规治疗基础上给予曲克芦丁脑蛋白进行辅助治疗,并将两组临床总有效率及不良反应发生率进行对比。另外,将两组治疗前、治疗后ESS评分变化情况进行对比。结果研究组临床总有效率为96.67%,较对照组的86.67%明显更高(χ2=6.548、P=0.011);研究组与对照组治疗前ESS评分为(59.46±8.73)分、(60.28±8.39)分,组间对比差异无统计学意义(t=-0.371、P=0.712);治疗后两组ESS评分均有所改善,治疗后第21天研究组及对照组ESS评分为(79.95±7.36)分、(73.23±8.50)分(t=3.274、P=0.002);研究组不良反应发生率为3.33%,较对照组的10.00%明显更低(χ2=3.576、P<0.05)。结论将曲克芦丁脑蛋白作为一种辅助药物对ACI患者进行治疗效果显著,可有效改善患者神经功能缺损,且无明显不良反应,用药安全性有保障,具备较高临床运用价值。

Objective To investigate the clinical efficacy of troxerutin protein in the treatment of acute cerebral infarction.Methods 60 patients with acute cerebral infarction admitted to the hospital from July 2015 to October 2017 were convenient selected and enrolled in the study.According to different treatment methods,they were divided into study group and control group,30 cases each.The control group was given an intravenous drip of 0.5 g of thrombus acupuncture needle+250 mL of normal saline,and another 100 mg of aspirin was orally administered.The study group received adjuvant treatment with troxerutin on the basis of conventional treatment,and compared the clinical total effective rate and incidence of adverse reactions between the two groups.In addition,the changes in ESS scores before and after treatment were compared between the two groups.Results The total effective rate of the study group was 96.67%,which was significantly higher than that of the control group 86.67%(χ^2=6.548,P=0.011).The ESS score of the study group and the control group before treatment was(59.46±8.73)points,(60.28±8.39)points.There was no significant difference between the groups(t=-0.371,P=0.712).The ESS scores of the two groups were improved after treatment.The ESS score of the study group and the control group on the 21st day after treatment was(79.95±7.36)points,(73.23±8.50)points(t=3.274,P=0.002);the incidence of adverse reactions in the study group was 3.33%,compared with 10.00%of the control group,significantly lower(χ^2=3.576,P<0.05).Conclusion The use of troxerutin as an auxiliary drug has a significant effect on the treatment of patients with ACI.It can effectively improve the neurological deficit of patients,and has no obvious adverse reactions.The safety of medication is guaranteed and has high clinical value.